by The global Integrase Inhibitors Market is estimated to be valued at US$ 29.34 Bn in 2023 and is expected to exhibit a CAGR of 3.9% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Integrase inhibitors are a class of antiretroviral drugs used in highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS. They work by inhibiting HIV integrase and blocking the integration of HIV DNA into the DNA of the infected human cells. They provide effective treatment option with less side effects and drug resistance as compared to other antiretroviral drugs.
Market key trends:
The AI-enabled healthcare applications are gaining traction in precision medicine for better treatment of various chronic diseases including HIV/AIDS. The increasing use of clinical decision support and diagnostic tools powered by artificial intelligence is expected to improve the treatment outcomes of HIV patients with Integrase inhibitors. AI tools allow real-time monitoring of patients health indicators and medication adherence which helps clinicians optimize therapy decisions. This is promoting the adoption of Integrase inhibitors especially in developed markets. Furthermore, favorable government policies and increasing R&D funding towards development of long-acting Integrase inhibitors is fueling the market growth over the forecast period.
Segment Analysis
The global integrase inhibitors market is dominated by the HIV segment. Integrase inhibitors are majorly used for the treatment of HIV infections. They work by blocking the integrase enzyme and preventing HIV from replicating in human cells. Integrase inhibitors have higher resistance barriers than other antiretroviral drug classes like nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). This makes them highly effective in controlling the HIV virus.
Key Takeaways
Global Integrase Inhibitors Market Size is expected to witness high growth, exhibiting CAGR of 3.9% over the forecast period, due to increasing research and development activities for developing new and improved drugs.
Regional analysis:
North America is expected to dominate the global integrase inhibitors market during the forecast period. The large share of this region can be attributed to growing prevalence of HIV and developed healthcare infrastructure. However, Asia Pacific is likely to exhibit the highest growth rate over the coming years due to increasing awareness about HIV treatments.
Key players:
Key players operating in the integrase inhibitors market are Gilead Sciences, ViiV Healthcare, Merck & Co., Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Janssen, Pharmaceuticals, Inc., Theratechnologies Inc., and Shionogi & Co., Ltd. Gilead Sciences dominates the global market with its blockbuster drug Biktarvy being the preferred first line treatment for HIV.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
